Management and grading of EGFR inhibitor-induced cutaneous toxicity

被引：28

作者：

Beech, Janette ^{[1
]}

Germetaki, Theodora ^{[1
]}

Judge, Mary ^{[2
]}

Paton, Nina ^{[1
]}

Collins, Joanne ^{[1
]}

Garbutt, Abigail ^{[3
]}

Braun, Michael ^{[1
]}

Fenwick, Jill ^{[4
,5
]}

Saunders, Mark P. ^{[1
]}

机构：

[1] Christie Hosp, Dept Med Clin Oncol, 550 Wilmslow Rd, Manchester, Lancs, England

[2] Salford Royal NHS Fdn Trust, Dept Dermatol, Salford, Lancs, England

[3] Christie Hosp Fdn Trust, Pharm, Manchester, Lancs, England

[4] Merck Serono Ltd, Feltham, England

[5] Merck KGaA, Darmstadt, Germany

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 24期

关键词：

acneiform eruptions; adverse reactions; cetuximab; drug-related side effects; EGFRI; metastatic colorectal cancer; panitumumab; paronychia; patient compliance; quality of life; receptor; treatment algorithm; GROWTH-FACTOR RECEPTOR; METASTATIC COLORECTAL-CANCER; QUALITY-OF-LIFE; SKIN TOXICITY; PHASE-II; CONTROLLED-TRIAL; CETUXIMAB; THERAPY; TETRACYCLINES; PANITUMUMAB;

D O I：

10.2217/fon-2018-0187

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors' clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. It aims to optimize treatment of metastatic colorectal cancer by minimizing cutaneous toxicities to maintain dose intensity and efficacy of EGFRI-based chemotherapy.

引用

页码：2531 / 2541

页数：11

共 40 条

[1]

Alberta Health Services, 2015, PAN CET TOX MAN GUID

[2]

[Anonymous], 2011, J CLIN ONCOL, DOI DOI 10.1200/JCO.2011.29.15_SUPPL.3576

[3]

[Anonymous], EGFR INH SKIN TOX TO

[4] DIFFERENCES IN PHOTOTOXIC POTENCY SHOULD BE CONSIDERED WHEN TETRACYCLINES ARE PRESCRIBED DURING SUMMER-TIME - A STUDY ON DOXYCYCLINE AND LYMECYCLINE IN HUMAN VOLUNTEERS, USING AN OBJECTIVE METHOD FOR RECORDING ERYTHEMA [J].

BJELLERUP, M ;

LJUNGGREN, B .

BRITISH JOURNAL OF DERMATOLOGY, 1994, 130 (03) :356-360

[5] Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results [J].

Boone, Susan L. ;

Rademaker, Alfred ;

Liu, Dachao ;

Pfeiffer, Carmen ;

Mauro, David J. ;

Lacouture, Mario E. .

ONCOLOGY, 2007, 72 (3-4) :152-159

[6] NCCN Task Force Report: Management of Dermatologic and Other Toxicities Associated With EGFR Inhibition in Patients With Cancer [J].

Burtness, Barbara ;

Anadkat, Milan ;

Basti, Surendra ;

Hughes, Miranda ;

Lacouture, Mario E. ;

McClure, Joan S. ;

Myskowski, Patricia L. ;

Paul, Jennifer ;

Perlis, Clifford S. ;

Saltz, Leonard ;

Spencer, Sharon .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2009, 7 :S5-S21

[7] How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? [J].

Chan, Alexandre ;

Tan, Eng Hooi .

SUPPORTIVE CARE IN CANCER, 2011, 19 (10) :1667-1674

[8] Measurement properties of Skindex-16: A brief quality-of-life measure for patients with skin diseases [J].

Chren, MM ;

Lasek, RJ ;

Sahay, AP ;

Sands, LP .

JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2001, 5 (02) :105-110

[9] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[10] Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy [J].

Eilers, R. E., Jr. ;

Gandhi, M. ;

Patel, J. D. ;

Mulcahy, M. F. ;

Agulnik, M. ;

Hensing, T. ;

Lacouture, Mario E. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (01) :47-53

← 1 2 3 4 →